Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED STATEMENTS OF CASH FLOWS

v3.22.1
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Cash flows from operating activities:    
Net loss $ (15,984,835) $ (3,867,984)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 1,961,733 74,384
Share-based compensation 1,230,792 1,030,802
Amortization of right-of-use asset 100,160 77,983
Amortization of debt discount 26,728 102,028
Non-cash interest 365,880 414,654
Convertible note issued for professional services 75,000 50,000
Deferred taxes (150,000)  
Changes in operating assets and liabilities:    
Accounts receivable and unbilled receivable (131,509)  
Prepaid expense and other assets (349,502) (318,380)
Other receivables 8,540  
Security deposit 2,592  
Accounts payable 41,130 114,290
Accounts payable - related party (15,725) 15,725
Accrued expenses 961,795 200,552
Accrued fiduciary obligations 1,470,159  
Operating lease liabilities (99,884) (86,971)
Due to related party (240,001) 243,638
Other liabilities (39,972)  
Other asset (28,333)  
Net cash used in operating activities (10,795,252) (1,949,279)
Cash flows from investing activities:    
Cash and restricted cash acquired as part of Acquisition (see Note 4) 11,384,035  
Capitalization of software development costs (1,463,812) (568,959)
Purchases of intangible asset (3,050)  
Purchase of property and equipment (273,433) (30,746)
Reimbursement of leasehold improvements from sublease   45,640
Net cash provided by (used in) investing activities 9,643,740 (554,065)
Cash flows from financing activities:    
Proceeds from initial public offering, net 25,378,663  
Proceeds from warrant exercises 900,000  
Repayment of convertible note (783,257)  
Proceeds from stock option exercises 61  
Proceeds from convertible notes 550,000 4,075,000
Proceeds from short-term loan 3,000,000  
Repayment of short-term loan (3,000,000)  
Payment for initial public offering costs (831,577)  
Proceeds from issuance of warrants 53,333  
Net cash provided by financing activities 25,267,223 4,075,000
Net increase in cash, cash equivalents and restricted cash 24,115,711 1,571,656
Cash, cash equivalents and restricted cash at beginning of period 1,817,932 246,276
Cash, cash equivalents and restricted cash at end of period 25,933,643 1,817,932
Reconciliation of cash, cash equivalents, and restricted cash reported in the consolidated balance sheet    
Cash and cash equivalents 19,183,044 1,754,569
Restricted cash 6,750,599 63,363
Total cash, cash equivalents and restricted cash shown in the consolidated statement of cash flows 25,933,643 $ 1,817,932
Supplemental disclosure of non-cash activity    
Conversion of convertible notes into common stock at the closing of the Acquisition, net 4,089,921  
Conversion of convertible notes into common stock at the IPO 5,106,554  
Office improvements included in accrued expenses 27,567  
Common stock issued as part of the Acquisition $ 8,500,000